Tomoko Motomiya

6PUBLICATIONS
5CO-AUTHORS
MortalityHumanitarian disasters, conflict and peacebuildingPharmacogenomicsMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 20, 2026
Response to Durability of zuranolone in postpartum depression versus major depressive disorder.

|Apr 23, 2026
Analysis of depressive symptom trajectory patterns with zuranolone: Time-series clustering of Japanese Phase 2 and Phase 3 trial data.

|Feb 23, 2026
Safety and efficacy of zuranolone in Japanese adults with major depressive disorder: An open-label, repeated-treatment part of a Phase 3 clinical trial.

Masaki Kato, Kazuyuki Nakagome, Takamichi Baba

|Nov 18, 2025
Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial.

Masaki Kato, Kazuyuki Nakagome, Takamichi Baba

|Jun 27, 2023
Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial.

Takuhiro Sonoyama, Ryosuke Shimizu, Ryuji Kubota

|May 30, 2023
Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.

Masaki Kato, Kazuyuki Nakagome, Takamichi Baba

Pageof 1

Frequent Collaborators

4 joint publications

Takeshi Inoue

3 joint publications

Masaki Kato

3 joint publications

Kazuyuki Nakagome

3 joint publications

Hiroki Fukuju